Brownstone Clinical Trials LLC — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$1,732	2
2024	Research	$7,421	5
2022	Research	$10,188	5
2021	Research	$5,472	5
2020	Research	$1,950	6
2019	Research	$12,055	8

Breakdown

Who paid Research payments · program years 2019–2025

Bayer HealthCare Pharmaceuticals Inc. $31,208 29 payments
Myovant Sciences Inc. $7,610 2 payments

Studies the money was for Research payments · program years 2019–2025

BAY1454033 pivotal $14,005 14 payments
Spirit Extension An International Phase 3 Open-Label, Single-Arm, Safety and Efficacy Extension Study to Evaluate Relugolix Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain $5,813 1 payment
A multi-centre, multi-national clinical study to evaluate the safety and effectiveness of the Essure (Model ESS505) device to prevent pregnancy in women who are seeking permanent contraception $5,100 3 payments
BAY1454033, pivotal $4,375 4 payments
An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure) or laparoscopic tubal sterilization $3,821 3 payments
BAY1454032 Essure System for Permanent Birth Control $3,675 4 payments
An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids $1,797 1 payment
An open-label, non-randomized, prospective observational cohort study to assess post-procedural outcomes in two cohorts of women who chose to undergo either hysteroscopic sterilization (Essure) or lap $232 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.